Leerink raises Moonlake stock price target on HS drug data

Leerink raised Moonlake Immunotherapeutics’ price target to $29 from $24 and increased the probability of success for sonelokimab in hidradenitis suppurativa to 90% from 75%, after Phase 3 VELA data showed 67% HiSCR75 and 33% HiSCR100 (396 patients). The company also announced a $200M public offering of 9.0M shares at $20.00 and pre-funded warrants for up to 1.0M more shares, which recently pressured the stock. Near-term catalysts remain strong, including the expected end-September biologics license application submission and additional Phase 3 readouts in 3Q/4Q 2026.

Analysis

MLTX is moving from a science story to a capital-allocation story. The key second-order effect is that a near-market equity raise materially reduces financing overhang, which can expand the investor base from event-driven funds to longer-only biotech holders ahead of the BLA, even if it creates short-term supply pressure. That matters because the next 6-18 months are less about another data print and more about whether management can keep credibility through regulatory acceptance and preserve optionality into the 2026 readouts.

The real competitive implication is not just in hidradenitis suppurativa; it is a read-through on the durability of differentiated IL-17 biology versus larger dermatology franchises at JNJ, ABBV, and UCB. If sonelokimab sustains high-remission signals without a safety tradeoff, it can pressure pricing assumptions and physician inertia in a niche but high-value inflammatory market. If the effect is merely incremental, the stock likely trades like a de-risked single-asset biotech with a long cash runway, not a platform winner.

Contrarianly, the market may be overweighting dilution and underweighting the fact that the raise likely funds the company through the most valuation-sensitive milestones. The downside case is not the offering itself; it is any sign that the BLA filing slips, priority review is denied, or the 2026 dermatology/rheumatology reads fail to broaden the label narrative. In that scenario, the stock can re-rate quickly back toward pure clinical optionality despite the cleaner balance sheet.

Key Decisions for Investors

• Tactically buy MLTX on post-offering weakness only if it holds the $19 secondary area for 2-3 sessions; target $27-$29 into BLA filing with a stop below $17 if the market treats the raise as a hard dilution overhang.
• For sector-neutral exposure, pair a long MLTX with a short XBI basket into the next 4-6 weeks to isolate idiosyncratic de-risking while avoiding broad biotech beta; the trade works if MLTX reclaims the offering price on volume.
• Do not add aggressively until the BLA acceptance decision is confirmed; if the filing is delayed or priority review is not granted, expect multiple compression back toward pre-data levels within 1-2 months.
• Watch ABBV, JNJ, and UCB as indirect losers only if future data show durable HiSCR100/remission rates; if not, treat this as a single-asset event and fade any claim of broad class disruption.